Re:Pair Genomics
Re:Pair Genomics uses machine learning to design compact, cell-type-specific synthetic regulatory DNA (promoters and enhancers) for gene therapies. It delivers ranked, synthesis-ready designs within about a day, compared with months of manual design and validation. Its customers are academic labs, biotech and pharma researchers working with AAV, lentiviral and non-viral vectors. It appears to sell design services and partnerships, but the pricing model is not public. It is a University of Toronto-linked startup that won second place at Medicine by Design's 2024 Building a Biotech Venture Pitch Competition (C$10,000). It received a 2025 grant from the Centre for Aging + Brain Health Innovation, and the amount is not disclosed.
Funding
Every round, secondary, debt facility or acquisition involving Re:Pair Genomics that AI Lounge tracks, newest first.
No rounds recorded yet.
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in